Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

ents with LV systolic dysfunction."

About Heart Failure

Heart failure is a chronic and progressive condition in which the heart cannot efficiently pump blood to meet the body's oxygen demands. The American Heart Association estimates that about 6 million Americans are living with heart failure, with 550,000 new cases diagnosed annually. Heart failure accounts directly for 55,000 deaths and indirectly for an additional 230,000 deaths in the United States each year. Heart failure is the underlying reason for approximately 12 to 15 million annual visits to physicians and 6.5 million annual hospital days.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead drug candidate, bucindolol, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to bucindolol. ARCA biopharma, in partnership with Laboratory Corporation of America (NYSE: LH), is developing a companion genetic test for bucindolol. For more information please visit http://www.arcabiopharma.com.


'/>"/>
SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ntario, Nov. 6 Helix Bio...) today announced that John Docherty, president an...n Curhan Ford,s 6th annual Investor Summit on Nove...ew York City. Mr. Docherty will provide an overvi...ograms L-DOS47 and Topical Interferon Alpha-2b. T...
(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/5/2009)...N, Colo., Nov. 5 The endangered bl...e western U.S. This rare carnivore feeds on prair...o plague and often entire population die-offs in t...(FWS) has implemented a ferret breeding program an... their formerly native habitat. Unfortunately, pl...
(Date:11/5/2009)...b., Nov. 5 Transgenomic,...inancial results for the quarter ended September 3...nted in the tables that follow. ,, Third Quart...$366,000 or $0.01 per share for the third quarter ...0.01 per share for the third quarter of 2008. ,...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...ent of Accurate Blood Test for Common Genetic Diso...., Jan. 27 Artemis Health Inc., a privately-held ...ve prenatal diagnostic tests, today announced that...from Stanford University to develop cell-free fe...ing research from the lab of Stephen Quake, Ph.D.,...
...wswire-Asia/ -- Pharmaxis Ltd (AXS: PXS,Nasdaq: ...port to Shareholders,on the afternoon of Wednesday... an investor teleconference the following morning ...s. , The teleconference will be on Thursday, 2...nuary at 4:30pm U.S. East Coast, 1:30pm U.S. West ...
...tics (NYSE Alternext US: CXM) today reported that ...any,s Board of Directors. The resignation reduces..."We thank Dr. Simon for his service to the Board a...ed Christopher J. Reinhard, Chairman and Chief Exe...: http://www.newscom.com/cgi-bin/prnh/20051018/CA...
Other Biology Technology:Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 2Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 3Cardium Announces Retirement of Director 2Cardium Announces Retirement of Director 3Cardium Announces Retirement of Director 4
(Date:11/4/2009)..., Nov. 4 GenVault Corporation (Car...., Ph.D., has joined its Board of Directors. Dr. ...Salk Institute, is an acclaimed physician-scientis...k Institute, Dr. Brody served as president of The ...ational Academy of Engineering and the Institute o...
(Date:11/3/2009)...be the ultimate loner of the ocean, cruising thous...searchers has discovered that the sharks have main... over tens of thousands of years the white sharks ...hemselves into a population genetically distinct f...ks are a large, highly mobile species," said Salva...
(Date:11/3/2009)...YETTE, Ind. - Chief executives in 35 of the top Fo...es their "ideal salaries" in 2008, according to a ...due University researcher to determine fair CEO co... and corporate governance issues of the day is how...nkat Venkatasubramanian, a professor of chemical e...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
... WHITE PLAINS, NY Babies born preterm were more t... full-term infants, according to a new analysis of...e this week in the Springer journal Maternal and C... before 37 completed weeks gestation, is a growing... Dimes. More than a half million babies are born t...
...own as neurons process information by joining into...her across junctions called synapses. But neurons ...Josh Huang, Ph.D., in a lot of cases, they connect... Dr. Huang, a professor at Cold Spring Harbor Lab...olecules guiding this highly specific neuronal tar...
...iologists from Austria and Singapore developed a t... between biology and art. In an article recently p...fasebj.org ) and scheduled for the August 2008 pri... able to coator paintviruses with proteins. This b... efficiency of some forms of gene therapy, help tr...
Other Biology News:Analysis of millions of US births shows association between birth defects and preterm birth 2Scientists discover a molecular scaffold that guides connections between brain cells 2Scientists discover a molecular scaffold that guides connections between brain cells 3Scientists 'paint' viruses to track their fate in the body 2
BMP-2 ELISA Kit from R&D Systems
5x MONO-RABBIT POLY C'GATE DILUENT from AbD Serotec
Argarase from BioVision
SAMPLE DILUENTS BUFFER TRIAL PACK from AbD Serotec
Biology Products: